On September 14, 2009
J&J Tinkers With Elan Deal, But It May Not Be Enough for Biogen
If Elan thinks that Johnson & Johnson’s reduction by $100 million of the $1 billion it agreed to pay for an 18.4 percent stake in Elan will fix their problem with Biogen, they may have another thing coming, according to a reading of the agreement between them. The judge wasn’t objecting to the price of deal, she was objecting to its form.
0 Comments